방광암 선별 검사로서 요 중 Melanoma Antigen Gene 검사와 요세포 검사의 비교 = Comparison of the Urinary Melanoma Antigen Gene Expression (MAGE) Test and Urinary Cytology for Bladder Cancer Screening

다국어 초록 (Multilingual Abstract)

Purpose: In bladder cancer screening, many methods such as urinary cytology, bladder tumor antigen, and nuclear matrix protein-22 are well known. To learn the value of urinary melanoma antigen gene expression (MAGE) in bladder cancer screening, we compared the urinary MAGE test with irrigated urinary cytology.
Materials and Methods: From July 2000 to July 2007, a total of 142 patients were enrolled in this study. We divided these patients into 2 groups. Eighty-eight patients with bladder cancer were included in group I. Group II consisted of 54 patients who had been treated for bladder cancer and had no evidence of tumor by cystoscopy and irrigated urinary cytology. Urinary cytology, urinary MAGE test, and cystoscopy were performed in all patients. The urinary MAGE test was done by reverse transcriptase polymerase chain reaction (RT-PCR). Sensitivity and specificity were investigated according to cancer grade and stage.
Results: The overall sensitivity of the urinary MAGE test and urinary cytology was 69.3% (61/88) and 53.4% (47/88), respectively (p=0.03). The specificity of the urinary MAGE test and urinary cytology was 75.9% (41/54) and 83.3% (45/54), respectively (p=0.34). The sensitivity of each test in superficial tumors (Ta, T1) was 65.5% (38/58) and 46.6% (27/58), respectively (p=0.04). In advanced disease (≥T2), the sensitivity of the tests was 76.7% (23/30) and 66.7% (20/30), respectively (p=0.39). The sensitivity of the urinary MAGE test in grade 1 tumors (60.5%, 23/38) was significantly higher (p=0.01) than that of urinary cytology (31.6%, 12/38).
Conclusions: The urinary MAGE test was more sensitive than urinary cytology in bladder cancer screening. We consider the urinary MAGE test to possibly be a valuable test together with urinary cytology, especially for Grade 1 and Ta, T1 bladder cancer.

다국어 초록 (Multilingual Abstract)

Purpose: In bladder cancer screening, many methods such as urinary cytology, bladder tumor antigen, and nuclear matrix protein-22 are well known. To learn the value of urinary melanoma antigen gene expression (MAGE) in bladder cancer screening, we compared the urinary MAGE test with irrigated urinary cytology.
Materials and Methods: From July 2000 to July 2007, a total of 142 patients were enrolled in this study. We divided these patients into 2 groups. Eighty-eight patients with bladder cancer were included in group I. Group II consisted of 54 patients who had been treated for bladder cancer and had no evidence of tumor by cystoscopy and irrigated urinary cytology. Urinary cytology, urinary MAGE test, and cystoscopy were performed in all patients. The urinary MAGE test was done by reverse transcriptase polymerase chain reaction (RT-PCR). Sensitivity and specificity were investigated according to cancer grade and stage.
Results: The overall sensitivity of the urinary MAGE test and urinary cytology was 69.3% (61/88) and 53.4% (47/88), respectively (p=0.03). The specificity of the urinary MAGE test and urinary cytology was 75.9% (41/54) and 83.3% (45/54), respectively (p=0.34). The sensitivity of each test in superficial tumors (Ta, T1) was 65.5% (38/58) and 46.6% (27/58), respectively (p=0.04). In advanced disease (≥T2), the sensitivity of the tests was 76.7% (23/30) and 66.7% (20/30), respectively (p=0.39). The sensitivity of the urinary MAGE test in grade 1 tumors (60.5%, 23/38) was significantly higher (p=0.01) than that of urinary cytology (31.6%, 12/38).
Conclusions: The urinary MAGE test was more sensitive than urinary cytology in bladder cancer screening. We consider the urinary MAGE test to possibly be a valuable test together with urinary cytology, especially for Grade 1 and Ta, T1 bladder cancer.

참고문헌 (Reference)

1 김성룡, "원발성 및 재발성 방광암 진단에 있어서 BTA TRAK 검사와 요세포검사의 비교" 대한비뇨기과학회 43 (43): 296-302, 2002

2 김덕윤, "방광암 진단을 위한 세 가지 요채집법에 따른 ThinPrep 검사와Melanoma Antigen Gene 역전사 중합효소연쇄반응법의 검출성적 비교" 대한진단검사의학회 27 (27): 50-55, 2007

3 권덕형, "방광암 진단에서 BTA TRAK, BTA stat, NMP22와 요세포검사의 임상적 효용성 비교" 대한비뇨기과학회 44 (44): 721-726, 2003

4 Murphy WM, "Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms" 53 : 1555-1565, 1984

5 Barker PA, "The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease" 67 : 705-712, 2002

6 De Plaen E, "Structure, chromosomal localization, and expression of 12 genes of the MAGE family" 40 : 360-369, 1994

7 Ianari A, "Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder" 49 : 786-789, 1997

8 Zeitlin S, "Pre-mRNA splicing and the nuclear matrix" 7 : 111-120, 1987

9 Bar-Haim E, "MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides" 91 : 398-407, 2004

10 Russo V, "MAGE BAGE, and GAGE genes expression in fresh epithelial ovarian carcinomas" 67 : 457-460, 1996

11 Sarosdy MF, "Improved detection of recurrent bladder cancer using the Bard BTA stat test" 50 : 349-353, 1997

12 Yamashita N, "High frequency of the MAGE-1 gene expression in hepatocellular carcinoma" 24 : 1437-1440, 1996

13 Murphy WM, "Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer" 136 : 815-819, 1986

14 Loening S, "Factors influencing the recurrence rate of bladder cancer" 123 : 29-31, 1980

15 Shichijo S, "Expression of the MAGE gene family in human lymphocytic leukemia" 41 : 90-103, 1995

16 Li J, "Expression of the MAGE gene family in human gastric carcinoma" 17 : 3559-3563, 1997

17 Kim YM, "Expression of MAGE-1,-2, and -3 genes in gastric carcinomas and cancer cell lines derived from Korean patients" 16 : 62-68, 2001

18 Patard JJ, "Expression of MAGE genes in transitional- cell carcinomas of the urinary bladder" 64 : 60-64, 1995

19 Mori M, "Expression of MAGE genes in human colorectal carcinoma" 224 : 183-188, 1996

20 Weynants P, "Expression of MAGE genes by non-small-cell lung carcinomas" 56 : 826-829, 1994

21 Russo M, "Expression of MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy" 64 : 216-221, 1995

22 Sharma S, "Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat" 162 : 53-57, 1999

23 Lokeshwar VB, "Current bladder tumor tests: Does their projected utility fulfill clinical necessity?" 165 : 1067-1077, 2001

24 Kinders R, "Complement factor H or a related protein is a marker for transitional cell cancer of the bladder" 4 : 2511-2520, 1998

25 Kim JS, "Comparison of the Bard BTA stat test, Bard BTA test, NMP-22 test and cytology in the diagnosis of bladder cancer" 41 : 833-837, 2000

26 Lotan Y, "Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker" 182 : 52-57, 2009

27 Raghavan D, "Biology and management of bladder cancer" 322 : 1129-1138, 1990

28 Lucas S, "A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells" 59 : 4100-4103, 1999

29 van der Bruggen P, "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma" 254 : 1643-1647, 1991